Announcing the launch of Avigan in India, Dr Reddy’s management said it is currently taking up studies with GRA in Kuwait and is in talks with various regulators in across the globe including the USFDA to seek fast-track approvals for Avigan. The generic drug maker hopes to complete the multi-ethnic trials on over 700 patients during the 10-12 weeks to submit them to various global drug regulators. Dr Reddy’s is currently taking up contract manufacturing of Remdesivir injection being administered intravenously in a hospital for treatment of severe Covid-19 under the license from Gilead Sciences and plans to launch its own product in India by September first week.
Currently in the process of technology transfer of Avigan from the Japanese drug maker, Dr Reddy’s hopes to obtain the approvals of the Drug Controller General of India to commence manufacture in India in a quarter or so. Meanwhile, apart from selling in India the antiviral drug imported from the Japanese company, Dr Reddy’s will also look at repackaging the Japanese drug to be sold in various overseas markets. Pricing Avigan in 200mg dosages at Rs 99 a tablet in a complete therapy pack of 122 tablets with a two-year shelf life, Dr Reddy’s has also made arrangements for free home delivery of the drug in 42 cities across India.